Literature DB >> 27895161

The E Loop of the Transmitter Binding Site Is a Key Determinant of the Modulatory Effects of Physostigmine on Neuronal Nicotinic α4β2 Receptors.

Xiaochun Jin1, Megan M McCollum1, Allison L Germann1, Gustav Akk1, Joe Henry Steinbach2.   

Abstract

Physostigmine is a well known inhibitor of acetylcholinesterase, which can also activate, potentiate, and inhibit acetylcholine receptors, including neuronal nicotinic receptors comprising α4 and β2 subunits. We have found that the two stoichiometric forms of this receptor differ in the effects of physostigmine. The form containing three copies of α4 and two of β2 was potentiated at low concentrations of acetylcholine chloride (ACh) and physostigmine, whereas the form containing two copies of α4 and three of β2 was inhibited. Chimeric constructs of subunits indicated that the presence of inhibition or potentiation depended on the source of the extracellular ligand binding domain of the subunit. Further sets of chimeric constructs demonstrated that a portion of the ACh binding domain, the E loop, is a key determinant. Transferring the E loop from the β2 subunit to the α4 subunit resulted in strong inhibition, whereas the reciprocal transfer reduced inhibition. To control the number and position of the incorporated chimeric subunits, we expressed chimeric constructs with subunit dimers. Surprisingly, incorporation of a subunit with an altered E loop had similar effects whether it contributed either to an intersubunit interface containing a canonical ACh binding site or to an alternative interface. The observation that the α4 E loop is involved suggests that physostigmine interacts with regions of subunits that contribute to the ACh binding site, whereas the lack of interface specificity indicates that interaction with a particular ACh binding site is not the critical factor.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27895161      PMCID: PMC5267520          DOI: 10.1124/mol.116.106484

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

1.  Differential α4(+)/(-)β2 Agonist-binding Site Contributions to α4β2 Nicotinic Acetylcholine Receptor Function within and between Isoforms.

Authors:  Linda M Lucero; Maegan M Weltzin; J Brek Eaton; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  J Biol Chem       Date:  2015-12-07       Impact factor: 5.157

2.  Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 nicotinic receptor influences agonist sensitivity.

Authors:  Simone Mazzaferro; Naïl Benallegue; Anna Carbone; Federica Gasparri; Ranjit Vijayan; Philip C Biggin; Mirko Moroni; Isabel Bermudez
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

3.  The nicotinic α5 subunit can replace either an acetylcholine-binding or nonbinding subunit in the α4β2* neuronal nicotinic receptor.

Authors:  Xiaochun Jin; Isabel Bermudez; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2013-11-01       Impact factor: 4.436

4.  Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.

Authors:  Kasper Harpsøe; Philip K Ahring; Jeppe K Christensen; Marianne L Jensen; Dan Peters; Thomas Balle
Journal:  J Neurosci       Date:  2011-07-27       Impact factor: 6.167

5.  Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes.

Authors:  J C Cooper; O Gutbrod; V Witzemann; C Methfessel
Journal:  Eur J Pharmacol       Date:  1996-08-15       Impact factor: 4.432

6.  Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

Authors:  Marek Samochocki; Anja Höffle; Andreas Fehrenbacher; Ruth Jostock; Jürgen Ludwig; Claudia Christner; Martin Radina; Marion Zerlin; Christoph Ullmer; Edna F R Pereira; Hermann Lübbert; Edson X Albuquerque; Alfred Maelicke
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

7.  Physostigmine modulation of acetylcholine currents in COS cells transfected with mouse muscle nicotinic receptor.

Authors:  Lucie Svobodová; Jan Krůsek; Tomás Hendrych; Frantisek Vyskocil
Journal:  Neurosci Lett       Date:  2006-03-13       Impact factor: 3.046

8.  Non-agonist-binding subunit interfaces confer distinct functional signatures to the alternate stoichiometries of the alpha4beta2 nicotinic receptor: an alpha4-alpha4 interface is required for Zn2+ potentiation.

Authors:  Mirko Moroni; Ranjit Vijayan; Anna Carbone; Ruud Zwart; Philip C Biggin; Isabel Bermudez
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

9.  Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine.

Authors:  A Schrattenholz; J Godovac-Zimmermann; H J Schäfer; E X Albuquerque; A Maelicke
Journal:  Eur J Biochem       Date:  1993-09-01

10.  Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor.

Authors:  Ayman K Hamouda; Tilia Kimm; Jonathan B Cohen
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

View more
  2 in total

1.  Determination of the Residues in the Extracellular Domain of the Nicotinic α Subunit Required for the Actions of Physostigmine on Neuronal Nicotinic Receptors.

Authors:  Xiaochun Jin; Allison L Germann; Daniel J Shin; Gustav Akk; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2017-06-19       Impact factor: 4.436

2.  The fifth subunit of the (α4β2)2 β2 nicotinic ACh receptor modulates maximal ACh responses.

Authors:  Karina New; Silvia Garcia Del Villar; Simone Mazzaferro; Constanza Alcaino; Isabel Bermudez
Journal:  Br J Pharmacol       Date:  2017-07-14       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.